Voluntary nationwide recall: Brexafemme

Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.

Recent Announcements

Training Webinar: Conversio Health COPD Management Program

Please join us for a live training webinar by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.
Jan. 2026Education/Webinars

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Jan. 2026Important Notices

UPMC Dental Advantage celebrates 15-years of growth

From pilot program to now serving all product lines
Jan. 2026What's New